MYELOMA MVP Trademark

Trademark Overview

On Monday, May 14, 2018, a trademark application was filed for MYELOMA MVP with the United States Patent and Trademark Office. The USPTO has given the MYELOMA MVP trademark a serial number of 87920209. The federal status of this trademark filing is REGISTERED as of Tuesday, November 26, 2019. This trademark is owned by Amgen Inc.. The MYELOMA MVP trademark is filed in the Advertising, Business and Retail Services category with the following description:

Promoting public awareness of health and medical issues; promoting public awareness of the dangers, diagnosis and treatment of blood disorders, cancers and multiple myeloma; promoting public awareness of the need to create plans to fight against blood disorders, cancers and multiple myeloma
myeloma mvp

General Information

Serial Number87920209
Word MarkMYELOMA MVP
Filing DateMonday, May 14, 2018
Status700 - REGISTERED
Status DateTuesday, November 26, 2019
Registration Number5921818
Registration DateTuesday, November 26, 2019
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 19, 2019

Trademark Statements

Disclaimer with Predetermined Text"MYELOMA"
Goods and ServicesPromoting public awareness of health and medical issues; promoting public awareness of the dangers, diagnosis and treatment of blood disorders, cancers and multiple myeloma; promoting public awareness of the need to create plans to fight against blood disorders, cancers and multiple myeloma
Pseudo MarkMYELOMA MOST VALUABLE PLAN

Classification Information

International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateMonday, May 21, 2018
Primary Code035
First Use Anywhere DateTuesday, July 17, 2018
First Use In Commerce DateTuesday, July 17, 2018

Trademark Owner History

Party NameAmgen Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799
Party NameAmgen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799
Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Trademark Events

Event DateEvent Description
Tuesday, November 26, 2019REGISTERED-PRINCIPAL REGISTER
Friday, October 25, 2019NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, October 24, 2019ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, October 23, 2019STATEMENT OF USE PROCESSING COMPLETE
Wednesday, October 2, 2019USE AMENDMENT FILED
Tuesday, October 22, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, October 2, 2019TEAS STATEMENT OF USE RECEIVED
Tuesday, April 16, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, March 7, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, March 7, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, February 19, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 19, 2019PUBLISHED FOR OPPOSITION
Wednesday, January 30, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, January 2, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 2, 2019EXAMINER'S AMENDMENT ENTERED
Wednesday, January 2, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, January 2, 2019EXAMINERS AMENDMENT E-MAILED
Wednesday, January 2, 2019EXAMINERS AMENDMENT -WRITTEN
Tuesday, December 18, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, December 17, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 17, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 15, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, June 15, 2018NON-FINAL ACTION E-MAILED
Friday, June 15, 2018NON-FINAL ACTION WRITTEN
Wednesday, June 13, 2018ASSIGNED TO EXAMINER
Monday, May 21, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, May 17, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

myeloma promoting awareness public disorders cancers multiple blood create plans